Epygenix Therapeutics Announces Appointment of G. Michael Landis as Chief Financial Officer
March 23, 2022 07:00 ET
|
Epygenix Therapeutics, Inc.
PARAMUS, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy, announces the...
Epygenix Therapeutics Announces Appointment of Darren Cline as CEO
March 15, 2022 07:00 ET
|
Epygenix Therapeutics, Inc.
PARAMUS, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy, announces the...
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
February 16, 2022 05:00 ET
|
Epygenix Therapeutics, Inc.
PARAMUS, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced...